Description:
The Lyme Elispot-LTT is designed to detect cellular activity in relation to Borrelia burgdorferi in chronic and acute cases of Lyme disease.
Checking whether a Lyme disease therapy has been successful is almost impossible, as Borrellia antibodies can be found in blood years after infection. The Elispot-LTT test for Borrelia closes this diagnostic gap, as it detects actual cellular activity in relation to Borrelia burgdorferi in chronic and also acute cases of Lyme disease. The Elispot-LTT test can detect 1 reactive T-cell per 100,000 lymphocytes. This is 20–200 times more sensitive than an ELISA Borrelia test.


LTT tests:
The LTT test reflects the actual, current Borrelia burgdorferi activity of chronic and also acute Lyme infections. The Elispot-LTT is highly sensitive and can detect even one single Borrelia-reactive T-cell in the blood. The Elispot-LTT is very helpful when monitoring a chronic or acute Lyme therapy, and should usually become negative about 6 to 8 weeks after completion of an effective therapy.
Tests for:
Chronic and acute Lyme disease, to determine duration of therapy and monitor treatment results after therapy


Symptoms and conditions:
  • Rash
  • Fever
  • Chills
  • Fatigue
  • Body aches
  • Headache
  • Joint pain
  • Neurological problems
  • Heart problems
  • Eye inflammation


Method:
Elispot LTT